AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31433920
Drug: Oral selinexor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly
Trial: 31434769
Drug: Antibiotic-related knowledge
RxNorm normalized name: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-related knowledge and attitudes in Chiang Rai
Trial: 31434769
Drug: Antibiotic-related knowledge
RxNorm normalized name: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-related knowledge and attitudes in Salavan
Trial: 31434769
Drug: Local expressions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local expressions for antibiotics in Chiang Rai
Trial: 31434783
Drug: Measurement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurement of influenza-specific antibody titres against all vaccinated and circulated strains during the 2016/2017 season
Trial: 31434793
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg per day orally plus another aromatase inhibitor
Trial: 31434940
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy in TNBC (n=239)
Trial: 31434940
Drug: Endocrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine treatment in ER+/HER2-/LN- (n=1113)
Trial: 31434940
Drug: Endocrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine treatment in ER+/HER2-/LN+ (n=423)
Trial: 31434940
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy and endocrine treatment in HER2+/ER+ (n=239)
Trial: 31434940
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy and endocrine treatment in ER+/HER2-/LN+ (n=433)
Trial: 31434940
Drug: Endocrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine treatment in ER+/HER2-/LN- untreated (n=200)
Trial: 31434940
Drug: HER2+/ER- with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER2+/ER- with anti-HER2+ ACT treatment (n=110)
Trial: 31434940
Drug: HER2+/ER+ with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER2+/ER+ with anti-HER2+ ACT + endocrine treatment (n=239)
Trial: 31438926
Drug: Discontinuation Prediction
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation Prediction Score (DiPS) using logistic regression and support vector machine methods
Trial: 31439037
Drug: MEDI0680 administered
RxNorm normalized name: MEDI0680
DrugBank: MEDI0680 (DB15768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0680 administered intravenously at doses of 0.1, 0.5, 2.5, 10, or 20 mg/kg Q2W or Q3W, with some cohorts receiving 20 mg/kg once a week for 2 or 4 weeks, then 20 mg/kg Q2W for a total treatment duration of 12 months or until progression.
Trial: 31439537
Drug: Carfilzomib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib at a dose of 20 mg/m²
Trial: 31440722
Drug: Lacosamide (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (adjunctive therapy)
Trial: 31440722
Drug: Lacosamide (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (adjunctive therapy) in SCB (+) subgroup (n=149)
Trial: 31440722
Drug: Lacosamide (adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (adjunctive therapy) in SCB (-) subgroup (n=153)
Trial: 31440946
Drug: Pasireotide (subcutaneous)
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pasireotide (subcutaneous)
Trial: 31442103
Drug: T-DM1 at
RxNorm normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib at 120, 160, 200, or 240 mg/d orally
Trial: 31442103
Drug: T-DM1 at
RxNorm normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib at 160 mg/d orally
Trial: 31442103
Drug: T-DM1 at
RxNorm normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib (various doses)
Trial: 31442327
Drug: Radium-223 re-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 re-treatment (up to 6 additional injections)
Trial: 31442817
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks) + Metronomic cyclophosphamide (50 mg b.i.d. one week on and one week off)
Trial: 31443741
Drug: Samalizumab (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samalizumab (50 to 600 mg/m)
Trial: 31444088
Drug: Pre-treatment pain
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment pain and dyspnea
Trial: 31581055
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks for up to 2 years
Trial: 31446142
Drug: Self-administered electronic
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered electronic screening for SUD risk, depression and anxiety using TAPS and AOQ measures
Trial: 31446511
Drug: Apalutamide 240
RxNorm normalized name: apalutamide 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalutamide 240 mg once-daily for 1 week, followed by continuous daily dosing (4 weeks/cycle)
Trial: 31446987
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine (Rova-T) 0.2 or 0.3 mg/kg by intravenous infusion on Day 1 of each 6-week cycle for 2 doses and dexamethasone (8 mg BID oral) on D-1, D1, and D2 of each 6-week cycle
Trial: 31448107
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise program after total hip arthroplasty, details on dosage and duration not available.
Trial: 31448214
Drug: Intensity-modulated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiation therapy (IMRT) with a prescription dose of 68.1 Gy in 30 fractions
Trial: 31449522
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for Buruli ulcer
Trial: 31450823
Drug: Anti-inflammatory therapy
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory therapy (CANTOS Trial, NCT01327846)
Trial: 31451367
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with first-line chemotherapy (capecitabine/oxaliplatin)
Trial: 31451367
Drug: Bevacizumab with
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with capecitabine-based chemotherapy vs fluorouracil-based regimens
Trial: 31451445
Drug: Blinatumomab, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab, 60 µg/m²
Trial: 31452586
Drug: Hyperglycemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (blood glucose level ≥ 169 mg/dL)
Trial: 31452586
Drug: Lower blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower blood glucose level (<169 mg/dL)
Trial: 31452902
Drug: Once-daily tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily tacrolimus dosing
Trial: 31452902
Drug: Twice-daily tacrolimus
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily tacrolimus dosing
Trial: 31453428
Drug: Monthly mailed
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly mailed healthy lifestyle intervention toolkit
Trial: 31455681
Drug: Mogamulizumab (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab (0.3 or 1.0 mg/kg) and Nivolumab (3.0 mg/kg)
Trial: 31455712
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with 1200 mg of elemental calcium during pregnancy and lactation
Trial: 31455851
Drug: Obinutuzumab plus
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab plus fludarabine and cyclophosphamide (G-FC)
Trial: 31456142
Drug: ONC201 (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 (administered orally once every week)
Trial: 31456261
Drug: Plerixafor 0.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor 0.32 mg/kg and bortezomib 1.3 mg/m²
Trial: 31456261
Drug: Plerixafor in
RxNorm normalized name: plerixafor Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor in combination with bortezomib
Trial: 31462437
Drug: Antibiotic use
RxNorm normalized name: Antibiotics for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic use in patients with viraemia
Trial: 31463078
Drug: Heavy-slow resistance
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy-slow resistance training (HSR) combined with ultrasound-guided corticosteroid injection
Trial: 31463362
Drug: Higher injection
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher injection pressure (550 pound/inch)
Trial: 31463362
Drug: Lower injection
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower injection pressure
Trial: 31463362
Drug: Higher injection
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher injection pressure
Trial: 31467699
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg of protein hydrolysate from Coldwater Shrimp
Trial: 31469058
Drug: Pressurized intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin/doxorubicin administered during standard laparoscopy
Trial: 31470902
Drug: Obinutuzumab (Gazyvaro)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab (Gazyvaro) combined with low-dose radiotherapy (LDRT)
Trial: 31471313
Drug: Regorafenib 120
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 120 mg/day
Trial: 31471313
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sunitinib and regorafenib
Trial: 31471312
Drug: GSK2816126 (EZH2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2816126 (EZH2 inhibitor) at doses ranging from 50 to 3,000 mg twice weekly, given 3-weeks-on/1-week-off in 28-day cycles
Trial: 31471376
Drug: Oral 5-azacytidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-azacytidine (AZA) 300 mg daily on days 1 to 14 and romidepsin (ROMI) 14 mg/m2 on days 8, 15, and 22 on a 35-day cycle
Trial: 31471376
Drug: Oral 5-azacytidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-azacytidine (AZA) 100 mg daily on days 1 to 14 to 300 mg daily on days 1 to 21 and romidepsin (ROMI) 10 mg/m2 on days 8 and 15 to 14 mg/m2 on days 8, 15, and 22
Trial: 31473727
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D 4000 IU/day for 6 months
Trial: 31473943
Drug: Quizartinib hydrochloride
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib hydrochloride (initial dose 20/30 mg/day)
Trial: 31474600
Drug: Conventional synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional synthetic disease-modifying antirheumatic drugs and/or tumor necrosis factor inhibitors
Trial: 31474848
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training with concurrent anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex
Trial: 31474848
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training with concurrent anodal transcranial direct current stimulation (tDCS)
Trial: 31475295
Drug: Sacubitril-valsartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril-valsartan treatment
Trial: 31475856
Drug: hs-cTnl concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnl concentrations <5 ng/L
Trial: 31475856
Drug: hs-cTnl concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnl concentrations <2 ng/L
Trial: 31476851
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab Vedotin (BV) administered intravenously at 1.8 mg/kg every 3 weeks
Trial: 31477052
Drug: Next generation
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Next generation sequencing of the T cell receptor (TCR) repertoire
Trial: 31477198
Drug: SSB intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSB intake at 5 years of age (100 ml/d increments)
Trial: 31477906
Drug: Low-affinity CD19
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-affinity CD19 CAR T cell therapy
Trial: 31479702
Drug: Pembrolizumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab with local therapy (stereotactic radiosurgery, surgery, or laser interstitial thermal therapy)
Trial: 31479702
Drug: Pembrolizumab without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab without local therapy
Trial: 31481121
Drug: Low-dose post-transplant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose post-transplant cyclophosphamide (14.5 mg/kg on days 3 and 4) with anti-thymocyte globulin (ATG)
Trial: 31481511
Drug: Galunisertib 150
RxNorm normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galunisertib 150 mg twice daily for 14 days on/14 days off
Trial: 31481566
Drug: Antirheumatic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antirheumatic treatments
Trial: 31481566
Drug: Comorbidities and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comorbidities and prescribed drugs identification
Trial: 31483485
Drug: sipuleucel-T immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sipuleucel-T immunotherapy (3 biweekly infusions)
Trial: 31483485
Drug: sipuleucel-T immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sipuleucel-T immunotherapy
Trial: 31485435
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for prostate cancer including novel therapies
Trial: 31485982
Drug: Rectal cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal cancer patients
Trial: 31487564
Drug: Lipid lowering
RxNorm normalized name: Lipid lowering agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid lowering therapy
Trial: 31488093
Drug: rs10132552 TC + CC
RxNorm normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs10132552 TC + CC
Trial: 31488216
Drug: HuMax-IL8 (BMS-986253)
RxNorm normalized name: Bms-986089 (fully human anti-myostatin adnectin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuMax-IL8 (BMS-986253) administered IV every 2 weeks at doses of 4, 8, 16, or 32 mg/kg
Trial: 31488216
Drug: HuMax-IL8 (BMS-986253)
RxNorm normalized name: Bms-986089 (fully human anti-myostatin adnectin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HuMax-IL8 (BMS-986253) administered IV every 2 weeks
Trial: 31488227
Drug: RESOLVE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RESOLVE plus treatment as usual (TAU)
Trial: 31488473
Drug: Self-reported preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported preventive measures and management strategies for knee symptoms (including non-pharmacological treatments and CAM)
Trial: 31491604
Drug: Hormone receptor-positive
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone receptor-positive and HER2-positive tumours
Trial: 31492778
Drug: Antidepression or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepression or antianxiety treatment among patients with ACS who received treatment after PCI.
Trial: 31492795
Drug: Concurrent use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent use of ≥2 CNSDs
Trial: 31493051
Drug: Clean Control
RxNorm normalized name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 0.2 g in 1 g TOPICAL STICK [Mitchum Clinical Soft Solid Clean Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clean Control (CC) group
Trial: 31494181
Drug: FOLFIRINOX ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX × 6 cycles, followed by radiation therapy (50 Gy in 25 fractions) concurrent with fixed-dose rate gemcitabine (1 g/m2)
Trial: 31495595
Drug: MenACWY-CRM booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM booster dose
Trial: 31496644
Drug: 0.01 mL
RxNorm normalized name: menthol 0.01 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mL (40 μg) intravitreal dexamethasone solution
Trial: 31496644
Drug: 0.03 mL
RxNorm normalized name: polyvinyl alcohol 0.03 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mL (120 μg) intravitreal dexamethasone solution
Trial: 31496644
Drug: 0.05 mL
RxNorm normalized name: xenon 0.05 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mL (200 μg) intravitreal dexamethasone solution
Trial: 31496644
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone solution
Trial: 31498564
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg once daily (D3-32)
Trial: 31498564
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg single oral doses (D1 and D31)
Trial: 31499518
Drug: PrEP first
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP first discontinuation
Trial: 31499518
Drug: PrEP final
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP final discontinuation
Trial: 31500586
Drug: Cetuximab in
RxNorm normalized name: cetuximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab in combination with irinotecan and fluorouracil
Trial: 31501123
Drug: Analgesic medication
RxNorm normalized name: ANALGESIC CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic medication use
Trial: 31501132
Drug: Daily screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily screening for readiness to discontinue MV
Trial: 31501132
Drug: Modes of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modes of MV used before initial discontinuation attempts
Trial: 31501132
Drug: Sedation and
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation and mobilisation practices to facilitate weaning and discontinuation
Trial: 31501975
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin type A (BoNT-A) treatment
Trial: 31502117
Drug: Aprutumab ixadotin
RxNorm normalized name: Anvatabart opadotin
DrugBank: Anvatabart opadotin (DB18290)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprutumab ixadotin (0.1-1.3 mg/kg, administered intravenously on day 1 of every 21-day cycle)
Trial: 31502400
Drug: Cediranib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cediranib at the pediatric maximum tolerated dose of 12 mg/m²
Trial: 31502421
Drug: Mepolizumab SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab SC 40 mg (bodyweight <40 kg) or 100 mg (≥40 kg) every 4 weeks for 12 weeks
Trial: 31502421
Drug: Mepolizumab SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab SC 40 mg or 100 mg
Trial: 31504335
Drug: CMV viremia
RxNorm normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV viremia (detected CMV DNA, median plasma viral load 498 IU/mL, IQR 259-2390)
Trial: 31504342
Drug: Depot Medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depot Medroxyprogesterone Acetate (DMPA) 150 mg intramuscular injection